N-AVD (nivolumab + AVD)
Checked 2026-09-09
Stage III-IV classical Hodgkin lymphoma, age 12 and above
One cycle
every 28 days × 6 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Nivolumab Monoclonal antibody (anti-PD-1) | 240 mg (3 mg/kg under 18 years) | IV | D1, 15 | |
Doxorubicin Cytotoxic chemotherapy (anthracycline) | 25 mg/m² | IV | D1, 15 | |
Vinblastine Vinca alkaloid (microtubule inhibitor) | 6 mg/m² | IV | D1, 15 | |
Dacarbazine | 375 mg/m² | IV | D1, 15 |
Cycles
6
28-day cycle
Emetogenicity
High (>90%)
G-CSF
Consider (10-20% FN risk)
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.